GLP-1 Market
LLY $1164.89 ▲ +1.0% NVO $39.80 ▼ -8.0% PFE $27.74 ▲ +0.3% VKTX $30.11 ▲ +3.9% KLRA $11.99 ▼ -6.5% GPCR $36.81 ▲ +5.2% RHHBY $55.30 ▲ +2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Plozasiran

Company
Arrowhead Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026

Find a Clinical Trial Near Me

See recruiting studies for Plozasiran and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06822790

    Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

    Not yet reported Arrowhead Pharmaceuticals 869 participants Est. completion 2028-07 255 sites Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
  • Recruiting NCT NCT06880770

    Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

    Not yet reported Arrowhead Pharmaceuticals 288 participants Est. completion 2029-06 140 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT03783377

    Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

    Not yet reported Arrowhead Pharmaceuticals 112 participants Est. completion 2021-02-11 10 sites Stand-alone
    Other conditions: Hypertriglyceridemia, Familial Chylomicronemia
    View official trial listing →
  • Completed NCT NCT04720534

    Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

    Not yet reported Arrowhead Pharmaceuticals 229 participants Est. completion 2023-08-31 74 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT04998201

    Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

    Not yet reported Arrowhead Pharmaceuticals 353 participants Est. completion 2023-08-14 30 sites Stand-alone
    Other conditions: Mixed Dyslipidemia
    View official trial listing →
  • Completed NCT NCT05089084

    Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

    Not yet reported Arrowhead Pharmaceuticals 75 participants Est. completion 2026-04-21 58 sites Stand-alone
    Other conditions: Familial Chylomicronemia
    View official trial listing →
  • Completed NCT NCT05413135

    Study of ARO-APOC3 in Adults With Dyslipidemia

    Not yet reported Arrowhead Pharmaceuticals 418 participants Est. completion 2025-09-22 60 sites Stand-alone
    Other conditions: Dyslipidemias
    View official trial listing →
  • Completed NCT NCT05902598

    A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

    Not yet reported Visirna Therapeutics HK Limited 37 participants Est. completion 2026-01-09 1 site Stand-alone
    Other conditions: Familial Chylomicronemia Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT06347003

    Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

    Not yet reported Arrowhead Pharmaceuticals 446 participants Est. completion 2026-09 196 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Active, not recruiting NCT NCT06347016

    Study of Plozasiran in Adults With Severe Hypertriglyceridemia

    Not yet reported Arrowhead Pharmaceuticals 311 participants Est. completion 2026-09 149 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Active, not recruiting NCT NCT06347133

    Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

    Not yet reported Arrowhead Pharmaceuticals 1456 participants Est. completion 2026-09 235 sites Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
  • Available NCT NCT06796426

    Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

    Arrowhead Pharmaceuticals 1 site
    Other conditions: Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Plozasiran, REDEMPLO, ARO-APOC3

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.